In four patients with NSCLC, on-target mechanisms were identified, including acquired secondary KRAS mutations associated with the switch II pocket to which KRAS inhibitors bind, Y96C, R86S, and H95D mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.